LAS VEGAS--(BUSINESS WIRE)--Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, announced today that the company’s investigational, non-steroidal anti-inflammatory drug (NSAID) submicron diclofenac reduced the use of opioid rescue medication in patients with acute pain following bunionectomy surgery. Specifically, the study showed that significantly fewer patients who received submicron particle diclofenac capsules 35 mg (82 percent; P = 0.002) or 18 mg (85 percent; P = 0.005), or who received active comparator celecoxib (85 percent; P = 0.006), required opioid-containing rescue medication for pain versus placebo (97 percent).
Help employers find you! Check out all the jobs and post your resume.
